Altimmune (ALT) News Mentions Statistics 2025

00%

1W 0% 1M 100% 3M 0%

Est. daily news mentions.

Similar companies

Company		News Mentions
	Amgen AMGN	2 0%
	Gilead Sciences GILD	0 0%
	Catalyst Pharmaceuticals CPRX	1 0%
	Inovio Pharmaceuticals INO	0 0%
	Anavex Life Sciences AVXL	0 0%

Analysts Set Altimmune, Inc. (NASDAQ:ALT) Target Price at $19.00

July 3

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Altimmune, Inc. - ALT

July 3

Pomerantz Law Firm Investigates Claims On Behalf of Investors of Altimmune, Inc. - ALT

July 1

INVESTOR ALERT: Investigation of Altimmune, Inc. (ALT) Announced by Holzer & Holzer, LLC

June 26

Altimmune Stock Sinks After Mid-Stage Data From Fatty Liver Candidate

June 26

Altimmune’s stock plummets over 60% as liver drug falls short in trial

June 26

Altimmune, Bit Digital, Kratos Defense & Security Solutions And Other Big Stocks Moving Lower In Thursday's Pre-Market Session

June 26

Month over Month

Est. daily news mentions.

Jun 2025	0	26.2%
May 2025	0	125.8%
Apr 2025	0	38%
Mar 2025	0	54.8%
Feb 2025	0

How often is Altimmune mentioned in the news?

Altimmune was mentioned an estimated 0 times in online prominent news articles yesterday.

Analyzing News Mentions, how is Altimmune performing compared to its industry peers?

Altimmune underperforms its industry peers when it comes to News Mentions, ranking dead last.

Has there been an increase or decrease in news mentions of Altimmune in the last month?

Altimmune's was mentioned in fewer articles yesterday, compared to the same day last month.

Why is it important to track news mentions for Altimmune?

By monitoring mentions in the news for Altimmune, investors stay up to date on impactful events for the company, its industry and its competitors. Positive news might affect price in a positive way and negative news might affect price in a negative way. By tracking mentions over time, investors can also identify patterns, explore popularity and make informed decisions based on the evolving perception of Altimmune, ultimately improving their investment strategies.

About Us

AltIndex revolutionizes investing with advanced alternative data analytics, smart insights, and stock alerts, presented in an easy-to-use dashboard powered by comprehensive company data from across the internet.

Legal Disclaimer
The information provided by AltIndex is solely for informational purposes and not a substitute for professional financial advice. Investing in financial markets carries inherent risks, and past performance doesn't guarantee future results. It's crucial to do your research, consult with financial experts, and align your financial objectives and risk tolerance before investing. AltIndex creators and operators are not liable for any financial losses incurred from using this information. Users should exercise caution, seek professional advice, and be prepared for the risks involved in trading and investing in financial assets, only investing what they can afford to lose. The information in this application, derived from publicly available data, is believed to be reliable but may not always be accurate or current. Users should verify information independently and not solely rely on this application for financial decisions. By using AltIndex, you acknowledge that it doesn't offer financial advice and agree to consult a qualified financial advisor before making investment decisions.

Top Stocks

Our Data

Datasets
Stock alerts
AI Stock Picks
AI Stock Picks - Results
House & Congress Trading
Earnings Calendar
Meme Stocks
Threads Users
Stock Predictor
Stock Picking Reviews
Stock Trading Signals
Index

AltIndex

News
Pricing
Sign up
Log in
API
Journalist Access
Data Disclaimer
Contact

Altimmune (ALT) - News Mentions

Similar companies

Amgen

Gilead Sciences

Catalyst Pharmaceuticals

Inovio Pharmaceuticals

Anavex Life Sciences

Analysts Set Altimmune, Inc. (NASDAQ:ALT) Target Price at $19.00

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Altimmune, Inc. - ALT

Pomerantz Law Firm Investigates Claims On Behalf of Investors of Altimmune, Inc. - ALT

Altimmune, Inc.(NasdaqGM: ALT) dropped from Russell 3000E Value Index

Altimmune, Inc.(NasdaqGM: ALT) dropped from Russell 3000 Value Index

Altimmune, Inc.(NasdaqGM: ALT) dropped from Russell 2500 Value Index

Altimmune, Inc.(NasdaqGM: ALT) dropped from Russell Small Cap Comp Value Index

Altimmune, Inc.(NasdaqGM: ALT) dropped from Russell 2000 Value Index

Altimmune, Inc.(NasdaqGM: ALT) dropped from Russell Microcap Value Index

HC Wainwright Reaffirms Buy Rating for Altimmune (NASDAQ:ALT)

Altimmune's Fatty Liver Candidate Faces Differentiation Doubts

GAMMA Investing LLC Purchases 4,598 Shares of Altimmune, Inc. (NASDAQ:ALT)

INVESTOR ALERT: Investigation of Altimmune, Inc. (ALT) Announced by Holzer & Holzer, LLC

Altimmune Stock Sinks After Mid-Stage Data From Fatty Liver Candidate

Altimmune’s stock plummets over 60% as liver drug falls short in trial

Altimmune, Bit Digital, Kratos Defense & Security Solutions And Other Big Stocks Moving Lower In Thursday's Pre-Market Session

Month over Month

How often is Altimmune mentioned in the news?

Analyzing News Mentions, how is Altimmune performing compared to its industry peers?

Has there been an increase or decrease in news mentions of Altimmune in the last month?

Why is it important to track news mentions for Altimmune?

Chat with AltIndex AI